Analyst firms · Guggenheim · OTLK
Guggenheim OTLK price target and rating history
Outlook Therapeutics Inc. (OTLK) · Health Care
Guggenheim rates Outlook Therapeutics Inc. (OTLK) Neutral with a $5 price target, as of its latest action on Aug 28, 2025. It has published 4 rating actions on OTLK since April 2023, including 1 upgrade and 2 downgrades.
- Current rating
- Neutral
- Price target
- $5
- Median target, all firms
- Too few
- Actions on OTLK
- 4
Every Guggenheim rating on OTLK
- Aug 28, 2025
- Jan 25, 2024
- Aug 30, 2023
- Apr 3, 2023
How other firms rate OTLK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Piper Sandler | Overweight | $4 | Nov 19, 2026 |
| BTIG | Buy | $4 | Jul 27, 2026 |
Questions about Guggenheim and OTLK
- What is Guggenheim's price target for OTLK?
- Guggenheim's latest stated price target for Outlook Therapeutics Inc. (OTLK) is $5, from its action on Apr 3, 2023.
- What is Guggenheim's rating on OTLK?
- Guggenheim rates OTLK Neutral, a neutral rating, as of Aug 28, 2025.
- When did Guggenheim last change its view on OTLK?
- On Aug 28, 2025, Guggenheim downgrades to Neutral from Buy.
More OTLK rating histories
All Guggenheim ratingsOTLK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.